NewMediaWire distributes press releases on behalf of hundreds of publicly traded companies, as well as private corporations, non-profits and other public sector organizations. Founded and staffed by industry veterans, we offer a full complement of services including specialized delivery to financial sites and posting of photos and multimedia content. In addition, NewMediawire offers international and specialized services such as IR websites and industry specific distribution.
RSS Feed for NewMediaWireNovember 10, 2025 — Research Highlights: Chest pain may still be angina even when the main heart arteries look clear. Using cardiac stress MRI (a heart scan that measures blood flow with magnetic resonance imaging), testing uncovered small vessel problems in about half of participants in a study of people who had prior coronary angiography that indicated no obstructive coronary artery disease.
November 10, 2025 — Research Highlights: Two P2Y12 inhibitors often used interchangeably, ticagrelor and prasugrel (antiplatelet medications prescribed to prevent the formation of blood clots), had different impacts on outcomes in patients with Type 1 or Type 2 diabetes who had undergone stent placement, a procedure done to keep an artery open, and free of clots or a blockage. While both medications help prevent platelets from clumping together and forming a clot in a stent, the study showed they may not offer the same level of benefits in the patients studied.
November 10, 2025 — Positioning GeoVax as a Diversified, Made-in-America Vaccine Leader with Global Market Relevance ATLANTA, GA - November 10, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today recognized World Immunization Day, a global observance highlighting the lifesaving power of vaccines and the urgent need to address rising concerns about vaccine confidence.
November 10, 2025 — Embargoed until 4:00 am CT/5:00 am ET, Monday, Nov. 10, 2025 DALLAS, TX - November 10, 2025 (NEWMEDIAWIRE) - Hundreds of health care artificial intelligence (AI) tools have been cleared by the U.
November 9, 2025 — Smart Technology and Sustainability Take Centre Stage The Hong Kong International Optical Fair came to a successful conclusion today, attracting some 12,000 buyers keen on sourcing and procurement Buyers from outside Hong Kong primarily came from the Chinese Mainland, Taiwan, India, Japan, Korea, the US, and ASEAN countries such as Indonesia, Malaysia, the Philippines and Thailand Fair products focused on key market trends - “smart technology”, “sustainability”, “silver healthcare” and “functionality & design” - featuring the industry's latest achievements in technological innovation and sustainability Results of the 25th Hong Kong Eyewear Design Competition showcased award-winning entries from local designers HONG KONG - November 9, 2025 (NEWMEDIAWIRE) - 7 November 2025, The 33rd Hong Kong International Optical Fair, organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Optical Manufacturers Association (HKOMA), concluded successfully today. The three-day fair attracted some 12,000 buyers from 92 countries and regions.
November 9, 2025 — Wine & Spirits Zone in the Spotlight With Global Demand for Diverse Wines and Spirits The three-day 17th Hong Kong International Wine & Spirits Fair ended yesterday, attracting over 8,200 trade buyers from 57 countries and regions The new “World of Spirits” zone showcased spirits from 14 countries and regions, featuring six of the “Top 10 Chinese Baijiu Brands” Homegrown brands injected authentic Hong Kong character and gained recognition from overseas buyers. HONG KONG - November 9, 2025 (NEWMEDIAWIRE) - The 17th Hong Kong International Wine & Spirits Fair (Wine & Spirits Fair), organised by the Hong Kong Trade Development Council (HKTDC), successfully wrapped up yesterday.
November 9, 2025 — Research Highlights: Adults in rural villages in China who participated in the Healthy Family Program, a family-based intervention that involved regular blood pressure monitoring, the use of low-sodium salt substitutes and educational sessions on healthy lifestyle habits, achieved an average of 10 mm Hg reduction in systolic blood pressure compared to adults who did not participate in the program. Six months after the program ended, the average systolic blood pressure for people who lived in participating villages remained 3.
November 9, 2025 — Research Highlights: A grocery support program based on the low-sodium DASH eating plan that included home-delivered groceries and dietary counseling reduced blood pressure levels in Black adults living in areas where grocery stores were inaccessible or scarce, known as food deserts. People who had groceries delivered to their homes and followed guidance from a dietitian for three months had greater improvements in blood pressure and cholesterol levels, compared to a similar group in the same community who were given a monthly stipend to purchase groceries and plan meals on their own.
November 9, 2025 — Research Highlights: A study of 400 adults with high blood pressure found that participants were twice as likely to take their blood pressure medication (measured by electronic pill bottles that recorded when bottles were opened) when they could win a daily cash reward compared to people who were not offered a potential reward. Despite taking their blood pressure medication more consistently, participants who were eligible for cash rewards had similar blood pressure reductions compared to the people who were not offered rewards.
November 9, 2025 — DALLAS, TX - November 9, 2025 (NEWMEDIAWIRE) - More than 28 million people worldwide are living with heart valve disease, and the numbers are climbing. In the U.
November 9, 2025 — Research Highlights: Adults with heart disease prescribed vitamin D in doses tailored to reach blood levels considered optimal for heart health (>40-80 ng/mL) had a reduced risk of heart attack by more than half (52%) compared to those who did not receive monitoring of vitamin D levels. 85% of all study participants had vitamin D levels below 40 ng/mL at enrollment, and nearly 52% of people in the treatment group needed to take more than 5,000 IU of vitamin D each day (more than six times the 800 IU daily value established by the FDA) to reach target blood levels of 40-80 ng/mL.
November 9, 2025 — Research Highlights: During the 6 months after treatment to restore a normal heart rhythm, adults with atrial fibrillation (AFib) who were randomly assigned to drink coffee every day were 39% less likely to have a recurrence of AFib compared to participants assigned to not have any coffee or other caffeinated drinks. The results of the 200-person trial may challenge the common belief that caffeine may spur more abnormal heart rhythms such as AFib.
November 9, 2025 — Research Highlights: Adults with atrial fibrillation and obesity/overweight (but no diabetes) who took the diabetes medication metformin after a rhythm correction procedure were more likely to stay free of AFib episodes for a year. Weight loss was not thought to be the main reason metformin helped, since there was only a modest weight change among those taking the medication.
November 8, 2025 — Research Highlights: Earlier blood transfusion after major surgery – when hemoglobin was below 10 g/dL rather than beow 7 g/dl - did not affect the risk of severe complications, such as death, heart attack, need for a heart procedure, kidney failure or stroke. However, the timing of the blood transfusion may be associated with a lower risk of irregular heartbeat and heart failure among people with heart disease, according to a new study of U.
November 8, 2025 — Research Highlights: Successful catheter ablation resulted in a low risk of stroke associated with atrial fibrillation (AFib), a type of irregular heart rhythm, according to an international study. Researchers said these findings may suggest that ongoing blood-thinning medication may not be needed after an ablation procedure.
November 8, 2025 — Research Highlights: Standard care, which included medication for those eligible, was better than a promising minimally invasive procedure for people with irregular heart rhythms who had high stroke and bleeding risk. The procedure seals off a small pouch of heart tissue, where most blood clots form in people with irregular heartbeat.
November 8, 2025 — Research Highlights: A one-month course of dual clot-preventing therapy followed by a single clot-prevention medication for the remainder of the standard 12-month regimen in adults with atrial fibrillation (AFib) who received a coronary stent was as effective as one year of continuous dual therapy for preventing stroke, heart attack and death. Participants treated with the one-month regimen experienced fewer bleeding problems than those in the year-long dual-treatment group.
November 8, 2025 — Research Highlights: For people who have experienced a heart attack or stroke, or who are at high risk of one and need further cholesterol lowering, a new daily pill may be a more convenient yet similarly effective option to injectable therapies. The oral medication, enlicitide, lowered LDL cholesterol by up to 60% and could eventually offer an option for people whose LDL levels remain above goal despite lifestyle changes and standard cholesterol medications like statins.
November 8, 2025 — Research Highlights: Results from the international VESALIUS-CV (TIMI 66) clinical trial found that among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes and no history of a prior heart attack or stroke, the PCSK9 inhibitor evolocumab reduced the risk of coronary heart disease death, heart attack, or ischemic stroke by 25%. Participants taking evolocumab also had a 19% reduction in the risk of coronary heart disease death, heart attack, ischemic stroke or arterial revascularization over a median of more than four and a half years follow-up.
November 8, 2025 — Research Highlights: In a Phase 1, first-in-human trial, a one-time infusion of an investigational CRISPR-Cas9 therapy targeting angiopoietin-like protein 3 (ANGPTL3) was safe and reduced LDL cholesterol by nearly 50% and reduced triglycerides by about 55%. Cholesterol and triglyceride levels began to drop within the two weeks after treatment, with effects sustained for at least 60 days of follow-up.